Legit Semaglutide

Semaglutide References: The Cited Literature

How these sources are used

Every quantitative claim on this site maps to one of the numbered sources below. They are the primary trial reports, dedicated safety and mechanism papers, and recent analyses behind the semaglutide record — peer-reviewed journals and PubMed-indexed studies. Where a paper is paywalled, the DOI and PubMed link still resolve to the abstract and metadata. No claim on this site exists without a source in this list.

  1. Wilding JPH, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. ↗
  2. Marso SP, et al. (SUSTAIN-6 Investigators). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. ↗
  3. Lincoff AM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. ↗
  4. Gabery S, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. ↗
  5. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. ↗
  6. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA: A Review. Int J Mol Sci. 2024;25(8):4346. ↗
  7. Perkovic V, et al. (FLOW Trial Committees and Investigators). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. ↗
  8. Husain M, et al. (PIONEER 6 Investigators). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-851. ↗
  9. Kosiborod MN, et al. (STEP-HFpEF Trial Committees and Investigators). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069-1084. ↗
  10. Kushner RF, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2022;24(3):527-536. ↗
  11. McCrimmon RJ, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity. J Endocr Soc. 2021;5(Suppl 1):A16-A17. ↗
  12. Mahapatra MK, et al. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative Diseases. Pharm Res. 2022;39(6):1233-1248. ↗
  13. Lincoff AM, et al. In adults with overweight or obesity and CVD but without diabetes, semaglutide reduced MACE (SELECT analysis summary). Ann Intern Med. 2024;177(3):JC30. ↗
  14. Rubino D, et al. (STEP 4 Investigators). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Maintenance (randomized withdrawal). JAMA. 2021;325(14):1414-1425. ↗
  15. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis. J Eur Acad Dermatol Venereol. 2025. ↗
  16. Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024. ↗
  17. Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. ↗
  18. Au Yeung SL, et al. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Saf. 2024. ↗
  19. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. ↗
  20. Frias JP, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE). Lancet Diabetes Endocrinol. 2021;9(9):563-574. ↗
  21. Aronne LJ, et al. (SURMOUNT-5 Investigators). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;392(20):2002-2014. ↗
  22. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk (modeling analysis). Eur Heart J Open. 2025;5(5):oeaf117. ↗